Related Experiment Video
Updated: Jun 21, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
[Benign prostatic hyperplasia].
Sarelis Infante Hernández1, Juan Gómez Rivas2, Jesús Moreno Sierra2
1Servicio de Urología, Hospital Clínico San Carlos, Madrid, España.
Benign prostatic hyperplasia (BPH), a common condition in aging men, causes lower urinary tract symptoms due to prostate enlargement. Treatment decisions for BPH are individualized based on quality of life and clinical factors.
Area of Science:
- Urology
- Geriatrics
Background:
- Benign prostatic hyperplasia (BPH) is a histopathologic finding of prostate enlargement.
- BPH commonly causes lower urinary tract symptoms (LUTS).
- LUTS prevalence increases with age, impacting quality of life.
Purpose of the Study:
- To review the diagnosis and treatment of BPH.
- To emphasize an individualized, risk-based approach for BPH management.
Main Methods:
- Review of clinical parameters and patient quality of life.
- Assessment of conservative, pharmacologic, and surgical treatment options.
Main Results:
- Prostate enlargement in BPH obstructs the lower urinary tract.
- Patient consultation is driven by characteristic clinical symptoms.
- Objective clinical parameters and quality of life are key to treatment decisions.
Conclusions:
- An individualized, risk-based approach is essential for managing BPH.
- Treatment strategies for BPH should be tailored to the patient's specific needs.
- Conservative, pharmacologic, or surgical interventions are guided by a comprehensive assessment.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Accessory Glands of the Male Reproductive System
The epididymis is a small, comma-shaped organ located at the back of each testicle. The epididymis can be divided into three main parts: the head, body, and tail. The head of the epididymis...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...

